Asset Details
Do you wish to reserve the book?
Non randomized study on the potential of nitisinone to inhibit cytochrome P450 2C9, 2D6, 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Non randomized study on the potential of nitisinone to inhibit cytochrome P450 2C9, 2D6, 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers
Do you wish to request the book?
Non randomized study on the potential of nitisinone to inhibit cytochrome P450 2C9, 2D6, 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Non randomized study on the potential of nitisinone to inhibit cytochrome P450 2C9, 2D6, 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers
2019
Overview
Purpose
Nitisinone inhibits the cytochrome P450 (CYP) subfamilies CYP2C9, CYP2D6, and CYP2E1 and the organic anion transporter (OAT) isoforms OAT1 and OAT3 in vitro
.
Since the effect of nitisinone on these enzymes and transporters in humans is still unknown, the purpose of this study was to evaluate the effect of nitisinone on these CYP subfamilies and OAT isoforms.
Methods
This was an open-label, nonrandomized, two-arm, phase 1 study (EudraCT: 2016-004297-17) in healthy volunteers. The substrates (tolbutamide, metoprolol, and chlorzoxazone for the respective CYPs and furosemide for the OATs) were administered as single doses, before and after 15 days of once daily dosing of 80 mg nitisinone, to determine the AUC
∞
ratios ([substrate+nitisinone]/[substrate]). Nitisinone pharmacokinetics, safety, and tolerability were also assessed, and blood and urine were collected to determine substrate and nitisinone concentrations by LC-MS/MS.
Results
Thirty-six subjects were enrolled with 18 subjects included in each arm. The least square mean ratio (90% confidence interval) for AUC
∞
was 2.31 (2.11–2.53) for tolbutamide, 0.95 (0.88–1.03) for metoprolol, 0.73 (0.67–0.80) for chlorzoxazone, and 1.72 (1.63–1.81) for furosemide. Clinically relevant nitisinone steady-state concentrations were reached after 12 days: mean C
av,ss
of 94.08 μM. All treatments were well tolerated, and no safety concerns were identified.
Conclusions
Nitisinone did not affect CYP2D6 activity, was a weak inducer of CYP2E1, and was a weak inhibitor of OAT1 and OAT3. Nitisinone was a moderate inhibitor of CYP2C9, and treatment may therefore result in increased plasma concentrations of comedications metabolized primarily via this enzyme.
Clinical trial registry identification
EudraCT 2016-004297-17.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Adult
/ Biomedical and Life Sciences
/ Cyclohexanones - adverse effects
/ Cyclohexanones - pharmacokinetics
/ Cyclohexanones - pharmacology
/ Cytochrome P-450 CYP2C9 - metabolism
/ Cytochrome P-450 CYP2D6 - metabolism
/ Cytochrome P-450 CYP2E1 - metabolism
/ Enzyme Inhibitors - adverse effects
/ Enzyme Inhibitors - pharmacokinetics
/ Enzyme Inhibitors - pharmacology
/ Female
/ Humans
/ Isoforms
/ Male
/ Nitrobenzoates - adverse effects
/ Nitrobenzoates - pharmacokinetics
/ Nitrobenzoates - pharmacology
/ Organic Anion Transport Protein 1 - antagonists & inhibitors
/ Organic Anion Transporters, Sodium-Independent - antagonists & inhibitors
/ Urine
